GARBO, EDOARDO
 Distribuzione geografica
Continente #
AS - Asia 510
NA - Nord America 471
EU - Europa 324
SA - Sud America 100
AF - Africa 11
OC - Oceania 1
Totale 1.417
Nazione #
US - Stati Uniti d'America 450
SG - Singapore 214
IT - Italia 199
CN - Cina 87
BR - Brasile 75
VN - Vietnam 61
KR - Corea 34
DE - Germania 33
BD - Bangladesh 29
FR - Francia 25
FI - Finlandia 22
HK - Hong Kong 18
IN - India 15
ID - Indonesia 13
JP - Giappone 13
CA - Canada 11
NL - Olanda 11
GB - Regno Unito 10
EC - Ecuador 8
AR - Argentina 5
IQ - Iraq 5
MX - Messico 5
PK - Pakistan 5
PY - Paraguay 4
UZ - Uzbekistan 4
VE - Venezuela 4
BE - Belgio 3
IE - Irlanda 3
JO - Giordania 3
MA - Marocco 3
SE - Svezia 3
UA - Ucraina 3
ZA - Sudafrica 3
AT - Austria 2
DZ - Algeria 2
ES - Italia 2
JM - Giamaica 2
LT - Lituania 2
PE - Perù 2
SN - Senegal 2
TR - Turchia 2
AF - Afghanistan, Repubblica islamica di 1
AU - Australia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BM - Bermuda 1
CL - Cile 1
CO - Colombia 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
KE - Kenya 1
KG - Kirghizistan 1
NP - Nepal 1
OM - Oman 1
PL - Polonia 1
PR - Porto Rico 1
RO - Romania 1
RU - Federazione Russa 1
SA - Arabia Saudita 1
SI - Slovenia 1
Totale 1.417
Città #
Singapore 136
Ashburn 88
San Jose 67
Santa Clara 64
Turin 46
Verona 34
Seoul 33
Dallas 31
Beijing 26
Hefei 26
Milan 24
Hanoi 20
Ho Chi Minh City 20
Hong Kong 17
Rome 17
Munich 15
Los Angeles 13
Tokyo 12
Lauterbourg 11
Jakarta 9
Lappeenranta 9
Turku 9
New York 8
Bengaluru 7
São Paulo 7
Buffalo 6
Columbus 6
Frankfurt am Main 6
Guangzhou 6
Nuremberg 6
Palermo 6
Atlanta 5
Boardman 5
Orem 5
Paris 5
Rio de Janeiro 5
The Dalles 5
Düsseldorf 4
Haiphong 4
Montreal 4
Amman 3
Amsterdam 3
Campinas 3
Chandler 3
Chennai 3
Da Nang 3
Dublin 3
Guayaquil 3
Mexico City 3
Nyköping 3
Phoenix 3
Silver Spring 3
Toronto 3
Asunción 2
Biên Hòa 2
Brooklyn 2
Charlotte 2
Dakar 2
Denver 2
Helsinki 2
Hải Dương 2
Johannesburg 2
Lima 2
Manchester 2
Miami 2
Mosul 2
Nichelino 2
Niterói 2
Pescara 2
Queens 2
Sale Marasino 2
Samarkand 2
Schaarbeek 2
Secaucus 2
Shanghai 2
Simpsonville 2
Sorocaba 2
Tashkent 2
Valatie 2
Valencia 2
Aberdeen 1
Acalanes Ridge 1
Agudos 1
Alexandria 1
Alvorada 1
Annaba 1
Arapiraca 1
Avudayapuram 1
Bady Bassitt 1
Barbacena 1
Bari 1
Bedford 1
Belo Horizonte 1
Bexley 1
Bilhorod-Dnistrovskyi 1
Birmingham 1
Boituva 1
Bologna 1
Bom Jesus do Itabapoana 1
Borgomanero 1
Totale 940
Nome #
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access program 179
Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies 125
Circulating tumor DNA dynamic variation predicts sotorasib efficacy in KRASp.G12C-mutated advanced non-small cell lung cancer 119
The evolving landscape of stage III unresectable non-small cell lung cancer "between lights and shadows" 117
Novel RAF‐directed approaches to overcome current clinical limits and block the RAS/RAF node 110
From Cancer to Immune Organoids: Innovative Preclinical Models to Dissect the Crosstalk between Cancer Cells and the Tumor Microenvironment 110
The biomarkers ATLAS: An audit on 1100 non-small cell lung cancer from an Italian knowledge-based database 109
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 107
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience 107
Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review 104
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review 94
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registry 43
Unraveling lung cancer dynamics: a new metabolic signature improving the prediction of recurrence in resected lung adenocarcinoma 27
LEAP-006: limits and potential of integrating anti-angiogenic agents into first-line multimodal therapy for non-squamous non-small cell lung cancer 10
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival 9
Neoadjuvant Chemoimmunotherapy in Stage III Non–Small Cell Lung Cancer—Reply 9
Brief Report: Critical Role for DNA-Based Sequencing in Discriminating Distinct Primary Lung Cancers With Different MET Exon 14 Skipping Mutations 9
Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors 8
Exploring genomic analysis and methylome profiling in longitudinal series of p.G12C KRAS mutated NSCLC patients treated with sotorasib 8
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancer 8
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 7
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC 7
First-Line MET Tyrosine Kinase Inhibitors versus Immunotherapy ± Chemotherapy for Patients with MET Exon 14 Skipping Mutant Metastatic NSCLC 6
Efficacy and Safety of Tarlatamab in a Patient With Advanced Delta-Like Ligand 3-Positive Large Cell Neuroendocrine Lung Carcinoma and Untreated Brain Metastases: A Case Report 6
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer 6
Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions 6
Antitumor Activity of Vebreltinib and Characterization of Clinicogenomic Features in Solid Tumors with MET Rearrangements 6
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathway 5
Totale 1.461
Categoria #
all - tutte 5.492
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.492


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202326 1 3 0 0 1 4 8 2 1 0 3 3
2023/202451 3 7 0 4 3 1 2 13 1 4 6 7
2024/2025323 2 24 14 18 64 23 10 9 41 22 35 61
2025/20261.019 67 144 74 102 103 29 81 43 73 77 69 157
2026/202742 42 0 0 0 0 0 0 0 0 0 0 0
Totale 1.461